Zitac vet. (10 - 20 kg)

3 x 10 pc

Tablet

Active substance

Cimetidine : 100 mg

ATC code

QA02BA01 Cimetidine

QA02BA H2-receptor antagonists

QA02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (GERD)

QA02 Drugs for acid related disorders

QA Alimentary tract and metabolism

Species

Dogs.

Indications

Symptomatic treatment for the reduction of vomiting associated with chronic gastritis in dogs.

Dose to be administered and administration route

For oral use.

Dose and route of administration: 5 mg of cimetidine per kg of bodyweight administered three times daily by the oral route (see indicative table below). The concomitant use of appropriate dietary measures is strongly recommended. In clinical trials the efficacy of cimetidine has only been studied concomitantly with a hypoallergenic diet.

Table: Number of Zitac vet 100 mg tablets to be administered three times daily according to body weight.

Weight (kg)	Number of Zitac vet 100 mg tablets
6 to 10	½
11 to 20	1

Recommended treatment scheme: reduction of vomiting is achieved in about 2 weeks. Animals should however be treated for at least 2 weeks after the remission of clinical signs, so a minimum treatment duration of 28 days is usually necessary and therefore recommended. If considered successful, medication should be withdrawn for 2 weeks. If vomiting occurs again, treatment can be re-initiated without risk of intolerance.

Depending on the response, treatment can be adapted to the individual animal until the response is considered to be adequate and continued. Dietary measures should always be maintained.

Adverse reactions

Dogs:

Very common

(>1 animal / 10 animals treated):

Mammary gland swelling¹

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Prostate weight reduction²

¹ Transient and self-resolving, slight swelling (gynaecomastia); anti-androgenic activity.

² reversible, with no impact on reproductive performances

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.